Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment
| Autor: | Aldo Bonaventura, Federica Biello, Franco Dallegri, Daniele Ferrara, Fabrizio Montecucco, Marco Tagliamento, Giovanni Rossi, Nicholas Bardi, Carlo Genova, E. Rijavec, Simona Coco, Anna Maria Ansaldo, A. Alama, Paolo Spallarossa, Federico Carbone, Francesco Grossi, M.G. Dal Bello, Alessandra Vecchié, Silvia Minetti, Edorado Elia |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Male Cancer Research medicine.medical_specialty Lung Neoplasms Neutrophils Immunotherapy Lung cancer Nivolumab NSCLC Resistin 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological Internal medicine Carcinoma Non-Small-Cell Lung Biomarkers Tumor Medicine Humans Prospective Studies Prospective cohort study Aged biology business.industry C-reactive protein General Medicine Middle Aged medicine.disease Prognosis Survival Rate 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis Absolute neutrophil count biology.protein Neutrophil degranulation Female business Blood sampling |
| Zdroj: | Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 22(9) |
| ISSN: | 1699-3055 |
| Popis: | Since the role of resistin was evaluated only in patients with non-small cell lung cancer (NSCLC) not treated with immunotherapy, we aimed to evaluate levels of resistin during immunotherapy (nivolumab) and its prognostic role with regard to OS. From a cohort of 78 patients with advanced NSCLC enrolled in a prospective study at Ospedale Policlinico San Martino in Genoa (Italy), 43 patients have been considered for this sub-analysis because of the availability of samples. Before and during nivolumab administration, clinical information and blood samples were collected and resistin, matrix metalloproteinase (MMP)-8, MMP-9, and myeloperoxidase were evaluated by enzyme-linked immunosorbent assay (ELISA). Median age was 71 with a prevalence of males and former smokers. Median resistin levels presented a peak at cycle 2 and then dropped down until the last cycle. Resistin correlated with all neutrophil degranulation products at cycle 1 (except for MMP-9) and at cycle 2 as well as with white blood cells and neutrophils. By a ROC curve analysis, a resistin value at cycle 2 of 19 ng/mL was tested as the best cut-off point for OS. Kaplan–Meier analysis demonstrated that patients above the resistin cut-off experienced a reduced OS (median OS 242.5 vs. 470 days, p = 0.0073), as confirmed by Cox proportional hazards regression analysis. Resistin levels > 19 ng/mL at the time of the second cycle of nivolumab treatment independently predict a reduced OS in patients with advanced NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink